Reprogrammed cellular metabolism is a common characteristic observed in various cancers 1,2 . However, whether metabolic changes directly regulate cancer development and progression remains poorly understood. Here we show that BCAT1, a cytosolic aminotransferase for branched-chain amino acids (BCAAs), is aberrantly activated and functionally required for chronic myeloid leukaemia (CML) in humans and in mouse models of CML. BCAT1 is upregulated during progression of CML and promotes BCAA production in leukaemia cells by aminating the branched-chain keto acids. Blocking BCAT1 gene expression or enzymatic activity induces cellular differentiation and impairs the propagation of blast crisis CML both in vitro and in vivo. Stable-isotope tracer experiments combined with nuclear magnetic resonance-based metabolic analysis demonstrate the intracellular production of BCAAs by BCAT1. Direct supplementation with BCAAs ameliorates the defects caused by BCAT1 knockdown, indicating that BCAT1 exerts its oncogenic function through BCAA production in blast crisis CML cells. Importantly, BCAT1 expression not only is activated in human blast crisis CML and de novo acute myeloid leukaemia, but also predicts disease outcome in patients. As an upstream regulator of BCAT1 expression, we identified Musashi2 (MSI2), an oncogenic RNA binding protein that is required for blast crisis CML. MSI2 is physically associated with the BCAT1 transcript and positively regulates its protein expression in leukaemia. Taken together, this work reveals that altered BCAA metabolism activated through the MSI2-BCAT1 axis drives cancer progression in myeloid leukaemia.
Reprogrammed cellular metabolism is a common characteristic observed in various cancers 1,2 . However, whether metabolic changes directly regulate cancer development and progression remains poorly understood. Here we show that BCAT1, a cytosolic aminotransferase for branched-chain amino acids (BCAAs), is aberrantly activated and functionally required for chronic myeloid leukaemia (CML) in humans and in mouse models of CML. BCAT1 is upregulated during progression of CML and promotes BCAA production in leukaemia cells by aminating the branched-chain keto acids. Blocking BCAT1 gene expression or enzymatic activity induces cellular differentiation and impairs the propagation of blast crisis CML both in vitro and in vivo. Stable-isotope tracer experiments combined with nuclear magnetic resonance-based metabolic analysis demonstrate the intracellular production of BCAAs by BCAT1. Direct supplementation with BCAAs ameliorates the defects caused by BCAT1 knockdown, indicating that BCAT1 exerts its oncogenic function through BCAA production in blast crisis CML cells. Importantly, BCAT1 expression not only is activated in human blast crisis CML and de novo acute myeloid leukaemia, but also predicts disease outcome in patients. As an upstream regulator of BCAT1 expression, we identified Musashi2 (MSI2), an oncogenic RNA binding protein that is required for blast crisis CML. MSI2 is physically associated with the BCAT1 transcript and positively regulates its protein expression in leukaemia. Taken together, this work reveals that altered BCAA metabolism activated through the MSI2-BCAT1 axis drives cancer progression in myeloid leukaemia.
To understand the contribution of α -amino acid metabolism to the cancer progression of CML, we analysed blood amino acid levels in mouse models that recapitulate the chronic and blast crisis phases of human CML 3, 4 . Using amine-specific fluorescent labelling coupled with high-performance liquid chromatography (HPLC), 16 amino acids were quantified in the blood plasma from leukaemic mice (Extended Data Fig. 1a-d ). Mice bearing blast crisis (BC)-CML showed moderate but significant elevations of plasma glutamate, alanine and the BCAAs (namely valine, leucine and isoleucine) compared with chronic phase (CP)-CML mice, indicating hyperaminoacidaemia (Extended Data Fig. 1e ). Intracellular levels of BCAAs and proline were higher in BC-CML, whereas intracellular glutamate and alanine were comparable in the two disease phases (Fig. 1a) . These results suggest that increased BCAA uptake or metabolism may contribute to CML progression. We analysed the gene expression and found no significant upregulation of known BCAA transporters in BC-CML compared with CP-CML (data not shown). Leucine import into BC-CML cells was not greater than into CP-CML cells (Extended Data Fig. 1f ), indicating that increased BCAA uptake does not explain the higher BCAA levels in BC-CML. To examine the possibility of altered intracellular BCAA metabolism, we next analysed the expression of genes encoding amino acid metabolic enzymes and found that the branched-chain amino acid aminotransferase 1 (Bcat1) was more highly expressed in BC-CML than in CP-CML at both the messenger RNA (mRNA) and protein levels (Fig. 1b-c and Extended Data Fig. 1g-h) . In contrast, normal haematopoietic stem/progenitor cells (HSPCs) from healthy mice had very low levels of Bcat1 expression (Lin − Sca-1 + c-Kit + (LSK) population; Fig. 1b ), and normal tissues did not show detectable Bcat1 expression except for the brain and testis (Extended Data Fig. 1i ). Bcat1 encodes an evolutionarily conserved cytoplasmic aminotransferase for glutamate and BCAAs, constituting a regulatory component of cytoplasmic amino acid and keto acid metabolism 5 (Fig. 1d and Extended Data Fig. 1j ). Bcat2, a paralogue encoding the mitochondrial BCAA aminotransferase, and alanine and aspartate aminotransferases did not show differential expression between CP-and BC-CML (Extended Data Fig. 1g , k-l).
Although BCAT1 catalyses transamination in both directions, the breakdown of BCAAs is the predominant reaction in most cell types 6 . For BCAT1 to generate BCAAs via the reverse reaction, the corresponding branched-chain keto acids (BCKAs), as well as glutamate, must be present as substrates. We found that all three BCKAs, keto-isovalerate (KIV), keto-isocaproate (KIC) and keto-methylvalerate were present in both the blood plasma and leukaemia cells (Extended Data Fig. 2a-d) . In BC-CML cells, BCKAs were present at concentrations equivalent to 22-55% of the corresponding BCAAs, suggesting that intracellular BCKAs can serve as substrates for BCAA production (Extended Data Fig. 2e ). Next, we examined whether BCAAs are produced through BCAT1 transamination reactions in leukaemia cells by stable-isotope tracer experiments with [ 13 C]valine or [ 13 C]KIV. Intracellular 13 C-labelled metabolites in K562 human BC-CML cells were analysed using one-and two-dimensional 1 H-13 C heteronuclear single-bond correlation (HSQC) analysis by high-field NMR spectroscopy (Fig. 1e-h and Extended Data Fig. 3 ). HSQC analysis detects only metabolites that have incorporated 13 C isotope. To determine whether KIV is converted to valine, cells were cultured in media supplemented with uniformly labelled [(U)- 13 C]KIV and non-labelled valine at physiological concentrations (30 and 170 μ M, respectively), and analysed for intracellular 13 C-labelled metabolites. After 15 min of labelling, the generation of [ 13 C]valine was clearly observed, indicating the efficient intracellular production of valine from KIV ( Fig. 1f, h) . In contrast, [ 13 C]KIV formation was barely detectable in the cells cultured with non-labelled KIV and [(U)-13 C]valine ( Fig. 1e , g). Our observation of intracellular [ 13 C]valine signals indicates its transport into BC-CML cells. We also detected robust signals for [ 13 C]KIV when present (Extended Data Fig. 3d , f). The formation of valine from KIV, but not the breakdown of valine to KIV, was also observed when we used equal concentrations of KIV and valine in the labelling media (170 μ M each; Fig. 1g , h). We did not detect KIC formation from [ 13 C]leucine either (Extended Data Fig. 3g -i). These results indicate that little, if any, BCAAs are catabolized to BCKAs in leukaemia cells. To provide further evidence for the intracellular BCAA production through transamination, we performed alternative labelling experiments to track the fate of the amine group of glutamate. We cultured K562 cells with [ 15 N]amine-labelled glutamine, which is metabolized to [ 15 N]amine-glutamate by glutaminase upon cellular intake, and analysed the subsequent labelling of BCAAs via 1 H NMR and 1 H-15 N heteronuclear multiple-bond correlation. This analysis detects only metabolites that have incorporated 15 N, whereas 1 H NMR detects any compounds containing protons (Extended Data Fig. 4a-f ). At 29-72 h after labelling, we detected 15 N-amine-labelled BCAAs, indicating transamination from glutamine to BCAAs (Fig. 1i ). By 72 h, the 15 N-amine-labelled BCAAs had accumulated to fractional abundances ranging from 24% to 39% (Extended Data Fig. 4g ), indicating a significant contribution of transamination to the intracellular BCAA pool. Lentiviral BCAT1 knockdown resulted in greater than a 50% decrease in the amount of intracellular BCAAs produced (Fig. 1j ). These data demonstrate that BCKA transamination by BCAT1 contributes to the BCAA pool in leukaemia cells.
Given that Bcat1 is highly expressed and augments intracellular BCAAs in BC-CML, Bcat1 may functionally contribute to the acute properties of BC-CML. To test this possibility, we inhibited Bcat1 expression using a short hairpin RNA (shRNA)-mediated gene knockdown approach. We sorted the immature lineage-negative (Lin − ) cells from primary BC-CML samples, a population that contains the leukaemia-initiating cells of this cancer, and introduced two independent retroviral shRNA constructs (Extended Data Fig. 1j ; shBcat1-a and shBcat1-b). Both constructs inhibited Bcat1 expression in BC-CML compared with a non-targeting negative control shRNA (shCtrl) (Extended Data Fig. 5a -c). Bcat1 knockdown resulted in significantly smaller colonies and a 40-60% reduction in the colony-forming ability relative to a control ( Fig. 2a ). The co-introduction of a shRNA-resistant Bcat1 cDNA rescued the reduced clonogenic potential (Extended Data Fig. 5d ). As an alternative approach to gene knockdown, we treated BC-CML cells with gabapentin (Gbp), a chemical inhibitor of BCAT1. Gbp is a structural analogue of leucine and specifically and competitively inhibits the transaminase activity of BCAT1 but not that of BCAT2 (ref. 7) . BC-CML cells plated with Gbp formed smaller colonies and showed a dose-dependent impairment in clonogenic growth ( Fig. 2b) . In contrast, normal HSPCs were only minimally affected by gene knockdown or Gbp treatment (Extended Data Fig. 5e , f). These data suggest that BCAT1 inhibition may selectively impair the propagation of leukaemia without affecting normal haematopoiesis.
To examine whether Bcat1 loss affects the propagation of BC-CML in vivo, Lin − cells expressing shBcat1 were transplanted into conditioned recipient mice. Whereas 75% of the recipients transplanted with control cells succumbed to the disease within 30 days, only 47% (shBcat1-a) and 31% (shBcat1-b) of the mice transplanted with Bcat1knockdown cells developed the disease, and more than half of these mice survived even when followed out to 60 days ( Fig. 2c ). Among the mice that developed disease with Bcat1 knockdown, most had leukaemia that was characterized by differentiated granulocytes and lower levels of immature myeloblasts ( Fig. 2d and Extended Data Fig. 5g ). They also displayed a lower frequency of immature Lin − cells than control leukaemia (Extended Data Fig. 5h ), indicating that the loss of Bcat1 induced differentiation and impaired the leukaemia-initiating cell activity. Consistent with these phenotypes, serial transplantation of the leukaemia cells revealed that while all the control leukaemia cells propagated the disease, none of the mice transplanted with Bcat1-knockdown leukaemia cells succumbed to the disease (line '1k' in Fig. 2e ). In addition, we established a doxycycline (Dox)-inducible Bcat1 knockdown system (i-shBcat1) and examined the impact of Bcat1 loss on the disease maintenance. Ten days after transplantation with BC-CML cells infected with i-shBcat1, leukaemic engraftment was assessed in each recipient, and Dox treatment was initiated (Extended Data Fig. 5i, j) . While almost all the mice that were transplanted with control cells and the non-Dox-treated mice developed leukaemia, more than half of the Dox-treated i-shBcat1 mice remained disease-free (Extended Data Fig. 5k ), indicating that Bcat1 is required for the continuous propagation of BC-CML. At the cellular level, we did not observe enhanced apoptosis or a decrease in actively cycling cells by Bcat1 knockdown (Extended Data Fig. 5l , m). These results demonstrate that Bcat1 is critical for the sustained growth and maintenance of leukaemiainitiating cells in BC-CML.
We next examined whether the enforced expression of Bcat1 could drive blastic transformation in haematopoietic cells. Although we observed a significant increase in Bcat1 expression compared with the vector control, Bcat1 expression alone did not enhance the colony-forming ability of either LSK or Lin − c-Kit + haematopoietic cells isolated from normal bone marrow (Extended Data Fig. 6a, b ). To determine whether BCR-ABL1 cooperates with Bcat1 overexpression to confer an aggressive growth phenotype, we transduced normal HSPCs with Bcat1 and BCR-ABL1. Compared with the vector control, the combinatorial expression promoted clonogenic growth in vitro (Extended Data Fig. 6c ), and the transplantation of the cells led to significantly elevated leukaemia burdens (Extended Data Fig. 6d , e), splenomegaly and increased mortality in the recipient mice ( Fig. 2f) , with a concomitant increase in plasma BCAA levels (Extended Data Fig. 6f ). Accordingly, leukaemia that developed in response to Bcat1 overexpression exhibited a highly immature myeloblastic morphology compared with the control ( Fig. 2g and Extended Data Fig. 6g ). These data indicate that activated Bcat1 mediates the blastic transformation of CP-CML cells.
Our results demonstrate that Bcat1 is essential for the development of BC-CML in mice, while normal bone marrow HSPCs show a very limited dependence on this metabolic enzyme. To investigate the contribution of BCAT1 to human leukaemia, we looked at a panel of 13 peripheral blood samples from healthy and leukaemic individuals and found human BCAT1 expression was higher in BC-CML than in either normal or CP-CML cells (Fig. 3a ). To determine whether this expression pattern reflects a general trend in human CML, we analysed BCAT1 levels in a Gene Expression Omnibus (GEO) dataset of 113 cases of CML 8 . This focused analysis revealed a significant elevation in BCAT1 expression as the disease progresses from the chronic to the accelerated phase and then to the blast crisis phase (Fig. 3b ). On average, BCAT1 expression was 15-fold higher in BC-CML than in CP-CML. We did not find significant changes in BCAT2 expression, which is consistent with the results from the mouse models ( Fig. 3c and Extended Data Fig. 1g ). These data indicate that activation of BCAT1 is a shared characteristic in the progression of human CML. Lentiviral BCAT1 knockdown or Gbp treatment markedly inhibited the colony-forming ability of K562 human BC-CML (Extended Data Fig. 7a-d ) and patient-derived primary leukaemia cells ( Fig. 3d , e and Extended Data Fig. 7e , f). Interestingly, we observed BCAT1 activation in primary human acute myeloid leukaemia as well (AML; Fig. 3f ), and Gbp effectively inhibited the clonal growth of human AML cell lines and primary de novo AML cells ( Fig. 3g and Extended Data Fig. 7g -i). Moreover, BCAT1 expression levels predict disease outcome in patient cohorts. Cases from The Cancer Genome Atlas (TCGA) AML dataset were divided into quartiles on the basis of BCAT1 expression levels (Extended Data Fig. 7j ), and we found that the median survival time was 46% shorter in the BCAT1-high group (427 versus 792 days; Fig. 3h ). These results demonstrate an essential role for BCAT1 in the pathogenesis of a wide array of human myeloid malignancies.
To understand how the BCAT1-driven change in metabolism promotes leukaemia growth, we analysed intracellular amino acid concentrations upon BCAT1 inhibition and found that all three BCAAs were significantly reduced by shBCAT1 or Gbp treatment compared with the controls (Extended Data Fig. 8a, b ). Interestingly, the addition of BCAAs, but not alanyl-glutamine (GlutaMax), functionally suppressed the reduction of colony-forming ability caused by BCAT1 knockdown (Fig. 3i ), suggesting that BCAT1 enhances clonogenic growth through BCAA production via BCKA reamination. BCAAs, particularly leucine, activate the mTORC1 pathway via cytosolic leucine sensor proteins, which integrate multiple signals from nutrient sensing and growth factor stimuli to promote cell growth [9] [10] [11] [12] . Thus, we examined whether reduced BCAA production by BCAT1 inhibition results in the attenuation of the mTORC1 signal. Indeed, BCAT1 blockade by either shRNA or Gbp treatment significantly reduced the phosphorylation of S6 kinase (pS6K), a downstream target of mTORC1 kinase ( Fig. 3j ), suggesting BCAT1 activation of the mTORC1 pathway. We observed no apparent changes in the levels of phosphorylated AKT upon BCAT1 inhibition, suggesting a predominant contribution of BCAA nutrient signals to the activation of mTORC1 (Extended Data Fig. 8c ). Consistently, the mTORC1 inhibitor rapamycin reversed the BCAA-induced suppression of colony formation ( Fig. 3i ) and the BCAA-induced increase in pS6K ( Fig. 3k ).
To further investigate the BCAT1-mediated regulation of CML progression, we performed gene correlation analyses using tumour gene expression datasets available in the GEO and TCGA databases. We found that BCAT1 and MSI2 are often co-expressed in several types of cancer, including leukaemias, colorectal and breast cancers (Extended Data Fig. 9a, b ). MSI2 is a member of the evolutionarily conserved Musashi RNA binding protein family, which regulates cell BC-CML cells expressing the indicated constructs were transplanted, and the survival of the recipients was monitored. shCtrl, n = 20; shBcat1-a, n = 19; shBcat1-b, n = 16. d, g, Percentage of immature myeloblasts in leukaemic mice. Photomicrographs of Wright's stained leukaemia cells. Arrowheads, immature myeloblasts; arrows, differentiating myelocytes and mature band cells. Scale bars, 10 μ m. e, Survival curve of mice serially transplanted with Lin − cells from primary shRNA-expressing leukaemias. One thousand cells per mouse (1k), n = 10 for shCtrl, n = 8 for shBcat1-a; and 3,000 cells per mouse (3k), n = 9 for shCtrl, n = 10 for shBcat1-a. f, Survival curve of mice transplanted with LSK cells infected with BCR-ABL1 (B/A) and the vector (Vec) control or Bcat1. n = 17 each. Inset, spleens from the indicated groups. Error bars, s.e.m. * P < 0.05, * * P < 0.01, * * * P < 0.001 by two-tailed t-test (d, g) or log-rank test (c, e, f).
fates during development and in multiple adult stem-cell systems in metazoans [13] [14] [15] . At the molecular level, Musashi proteins bind to r(G/A)U 1-3 AGU sequences (MSI binding elements, MBEs) and post-transcriptionally regulate gene expression via mRNA binding 16, 17 . Importantly, MSI genes are aberrantly activated in human malignancies, such as gliomas and breast and colorectal cancers 18, 19 . In human BC-CML, the MSI2 gene is upregulated and functionally required for the progression of this leukaemia 20, 21 . To determine whether BCAT1 is a direct target of the MSI2 RNA binding protein, we analysed the BCAT1 mRNA sequence and found 40 putative MBEs in the 3′ untranslated region (3′ UTR; Extended Data Fig. 9c ). To test whether MSI2 binds to the BCAT1 transcripts, we expressed a Flagtagged MSI2 protein in K562 cells and performed RNA immunoprecipitation (RIP). Flag-MSI2 co-precipitated the BCAT1 transcripts with a greater than 1,500-fold enrichment relative to the vector control ( Fig. 4a ). In contrast, when RIP was performed with a mutant MSI2 protein in which three phenylalanine residues essential for RNA binding were replaced with leucine 16 , the amount of the BCAT1 mRNA recovered was markedly diminished (Fig. 4a , RNA binding defective mutant (RBD)), indicating that the co-precipitation of BCAT1 transcript requires the RNA binding activity of MSI2. The transcripts for β -2-microglobulin (B2M) or c-Myc oncogene (MYC) contain only one copy of a putative MBE in their 3′ UTRs (data not shown), and MSI2 RIP did not enrich B2M or MYC mRNAs as efficiently as BCAT1 (Fig. 4a ). Furthermore, RIP with an anti-MSI2 antibody showed that endogenous MSI2 proteins bound to BCAT1 transcripts, while B2M or MYC mRNAs exhibited minimal enrichment relative to that of an immunoglobulin-G (IgG) control ( Fig. 4b) , indicating that MSI2 is specifically associated with the BCAT1 transcripts. Because MSI2 knockdown reduced the levels of BCAT1 protein and p-S6K (Extended Data Fig. 9d ), the binding of MSI2 to BCAT1 mRNA positively regulates BCAT1 translation and mTORC1 activation. Importantly, BCAT1 overexpression ( Fig. 4c ) and BCAA supplementation ( Fig. 4d ) effectively suppressed the attenuation of the colony-forming ability caused by MSI2 knockdown, with a concomitant increase in pS6K levels in a rapamycin-sensitive manner (Fig. 4e ). The levels of AKT phosphorylation were unaffected by shMSI2 (Extended Data Fig. 8c ). Collectively, our work presented here demonstrates an essential role for the MSI2-BCAT1 axis in myeloid leukaemia and provides a proof-of-principle for inhibiting the BCAA metabolic pathway to regulate CML progression (Fig. 4f) .
The upregulation and functional requirements of BCAT1 have been reported in glioblastoma and in colorectal and breast tumours 22, 23 . Interestingly, Musashi proteins also regulate the same spectrum of cancers including myeloid leukaemia [18] [19] [20] [21] 24, 25 , suggesting a highly conserved role for the MSI-BCAT1 pathway in multiple cancer types. Despite the conservation of this pathway, the metabolic role of BCAT1 seems distinct and dependent on the tissue of origin; in the brain, BCAT1 catalyses BCAA breakdown and glutamate production to enhance tumour growth in glioblastoma 23 , whereas it promotes BCAA production in leukaemia. Two different types of tumour, specifically pancreatic ductal adenocarcinoma and non-small-cell lung carcinoma, were recently shown to exhibit different usages of BCAAs 26 . Despite the same initiating events of KRAS activation and TP53 deletion, nonsmall-cell lung carcinoma cells actively utilize BCAAs by enhancing their uptake and oxidative breakdown to BCKAs, whereas pancreatic ductal adenocarcinoma cells display decreased uptake and thus little dependency on BCAAs. Consistently, BCAT1 and BCAT2 are required for tumour formation in non-small-cell lung carcinoma but not in pancreatic ductal adenocarcinoma. Although BCAT1 is functionally required for tumour growth in a broad range of malignancies, these reports and our studies highlight the context-dependent role of the BCAT1 metabolic pathway in cancer.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
Letter reSeArCH

MethODS
Mice. C57BL/6J mice were from the Jackson Laboratory. Mice were bred and maintained in the facility of the University Research Animal Resources at University of Georgia. All mice were 8-16 weeks old, age-and sex-matched and randomly chosen for experimental use. No statistical methods were used for sample size estimates. All animal experiments were performed according to protocols approved by the University of Georgia Institutional Animal Care and Use Committee. The investigators were not blinded to allocation during experiments and outcome assessment. Cell isolation, analysis and sorting. Cells were suspended for cell sorting in Hanks' balanced salt solution (HBSS) containing 5% (v/v) fetal bovine serum (FBS) and 2 mM EDTA as previously described 27 . The following antibodies were used to define lineage positive cells: 145-2C11 (CD3ε ), GK1.5 (CD4), 53-6.7 (CD8), RB6-8C5 (Ly-6G/Gr1), M1/70 (CD11b/Mac-1), TER119 (Ly-76/TER119), 6B2 (CD45R/B220) and eBio1D3 (CD19). Red blood cells were lysed with RBC Lysis Buffer (eBioscience) before staining for lineage markers. For the LSK bone marrow cell sorting, the antibodies 2B8 (c-Kit/CD117) and D7 (Sca-1/Ly-6A/E) were also used. To determine donor-derived chimaerism in the transplantationbased assays, peripheral blood from the recipients was obtained by the submandibular bleeding method and prepared for analysis as previously described 20 . All antibodies were purchased from eBioscience. Apoptosis assays were performed by staining cells with Annexin V and 7-AAD (BioLegend). Cell cycle status was analysed by staining cells with 2.5 μ g ml −1 PI containing 0.1% BSA and 2 μ g ml −1 RNase after fixation with 70% ethanol. Flow cytometric analysis and cell sorting were performed on the Moflo XDP, Cyan ADP (Beckman Coulter) or S3 (Bio-Rad), and the data were analysed with FlowJo software (Tree Star). Viral constructs and production. Retroviral BCR-ABL1 and NUP98-HOXA9 vectors and lentiviral FG12-UbiC-GFP vector were obtained from Addgene. Mouse Bcat1 cDNA (IMAGE clone ID 30063465) was cloned into MSCV-IRES-GFP and Human BCAT1 cDNA (NITE clone ID AK056255) was cloned into FG12-Ubc-hCD2. The short hairpin RNA constructs against Bcat1 (shBcat1) were designed and cloned in MSCV-LTRmiR30-PIG (LMP) vector from Open Biosystems or TtRMPVIR from Addgene according to their instructions. The target sequences are 5′-CCCAGTCTCTGATATTCTGTAC-3′ for shBcat1-a, 5′-TCCGCGCCGTTTGCTGGAGAAA-3′ for shBcat1-b and 5′-CTGTGCCAGAGTCCTTCGATAG-3′ for luciferase as a negative control (shCtrl). Lentiviral short hairpin RNA (shRNA) constructs were cloned in FG12 essentially as described previously 28 . The target sequences are 5′-CGCAGAGTGTACCGGAGA-3′ for shBCAT1-c, 5′-TGCCCAATGTGAAGCAGT-3′ for shBCAT1-d and 5′ -TGCGCTGCTGGTGCCAAC-3′ for luciferase as a negative control. Virus was produced in HEK 293FT cells transfected using polyethylenimine with viral constructs along with VSV-G and gag-pol. For lentivirus production Rev was also co-transfected. Viral supernatants were collected for two days followed by ultracentrifugal concentration at 50,000g for 2 h. Cell culture and colony-formation assays. The human BC-CML cell line K562, the human acute leukaemia cell lines MV4-11 and U937 were maintained in Roswell Park Memorial Institute 1640 medium (RPMI-1640) with 10% FBS, 100 IU ml −1 penicillin and 100 μ g ml −1 streptomycin. The human acute promyelocytic leukaemia cell line HL60 was maintained in RPMI media supplemented with 20% FBS. All human cell lines were mycoplasma-tested and obtained from the American Type Culture Collection, and cell line authentication testing was performed by American Type Culture Collection-standardized short tandem repeat profile analysis to verify their identity in July 2016. For the colony-formation assays, the cells were transduced with lentiviral shRNA and plated in triplicate in 1.2% methylcellulose medium (R&D systems) supplemented with 100 IU ml −1 penicillin and 100 μ g ml −1 streptomycin, 10% FBS. Where indicated, either BCAAs (l-leucine, l-valine, l-isoleucine, 4 mM each, Sigma-Aldrich), l-alanyl-l-glutamine (4 mM, GlutaMax, Life Technologies), rapamycin (50 nM, Tocris) or Gbp (Tokyo Chemical Industry Company) was added to the medium. Gbp was freshly dissolved in PBS buffer solution before use. Colonies were scored on days 9-14. For liquid culture of mouse cells, freshly isolated adult LSK cells or Lin − BC-CML cells were plated into a 96-well U-bottom plate in X-Vivo15 (with gentamicin and Phenol Red; Lonza) supplemented with 50 μ M 2-mercaptoethanol, 10% FBS, 100 ng ml −1 stem cell factor (eBioscience) and 20 ng ml −1 thrombopoietin (Peprotech). For the BC-CML and LSK colony-formation assays, BCR-ABL + NUP98-HOXA9 + or infected construct-positive cells were sorted and plated in triplicate in Iscove's modified medium (IMDM)-based methylcellulose medium (Methocult M3434, StemCell Technologies). Colonies were scored on days 7-10. Generation and analysis of leukaemic mice. Mice bearing CP-and BC-CML were generated essentially as previously described 3, 4, [29] [30] [31] . In brief, CP-CML was modelled by transducing the oncogene BCR-ABL1 into HSPCs defined by the LSK surface marker phenotype from normal bone marrow, which were transplanted into conditioned recipient mice. BC-CML was modelled by transplant-ing LSK cells infected with two oncogenes, BCR-ABL1 and NUP98-HOXA9, which are associated with myeloid BC-CML in humans. LSK cells were sorted from healthy C57BL/6J bone marrow and cultured in X-Vivo15 media supplemented with 50 μ M 2-mercaptoethanol, 10% FBS, 100 ng ml −1 stem cell factor and 20 ng ml −1 thrombopoietin. After incubation overnight, cells were infected with retroviruses carrying the oncogenes. Viruses used were as follows: MSCV-BCR-ABL-IRES-YFP to generate CP-CML, or MSCV-BCR-ABL-IRES-YFP and MSCV-NUP98-HOXA9-IRES-tNGFR to generate BC-CML. Cells were collected 48 h after infection and transplanted retro-orbitally into groups of C57BL/6J mice. Recipients were lethally irradiated (9.5 Gy) for CP-CML and sublethally (6 Gy) for BC-CML. For Bcat1 overexpression, LSK cells were infected with MSCV-BCR-ABL-IRES-YFP and MSCV-Bcat1-IRES-GFP, and doubly infected cells were purified by fluorescence-activated cell sorting and transplanted into recipients that were sublethally irradiated. For Bcat1 knockdown by retroviral shRNA transduction, the Lin − population from BC-CML cells was sorted and infected with either control shCtrl (against luciferase) or shBcat1-a/b (against Bcat1) retrovirus for 48 h. Infected cells were sorted on the basis of GFP expression, and 1,000 or 2,000 cells were transplanted in sublethally irradiated C57BL/6J recipients. For conditional Bcat1 knockdown by a Dox-inducible shRNA system, animals were analysed for donor chimaerism at day 10 after transplantation, and then Dox treatment was initiated by feeding Dox-containing rodent chow (0.2 mg g −1 diet; S3888, BioServ). After transplantation, recipient mice were maintained on antibiotic water (sulfamethoxazole/trimethoprim) and evaluated daily for signs of morbidity, weight loss, failure to groom and splenomegaly. Premorbid animals were euthanized, and relevant tissues were harvested and analysed by flow cytometry and histopathology. For secondary BC-CML transplantations, cells recovered from terminally ill primary recipients were sorted for Lin − donor cells and transplanted into secondary recipients. Where indicated, sorted live BC-CML cells from the spleen were cytospun and stained with Wright's stain solution (Harleco) for cytopathologic evaluation by a board-certified veterinary pathologist (T.N.). Primary human leukaemia samples. Blood samples from patients were obtained at the Institute of Medical Science Hospital, University of Tokyo, with written informed consent according to the procedures approved by the Institutional Review Board. Mononuclear cells from the individuals were viably frozen and stored in liquid nitrogen. For in vitro colony formation with BCAT1 knockdown, primary hCD34 + cells sorted from patients' bone marrow samples were cultured in IMDM supplemented with 10% FBS, 100 IU ml −1 penicillin and 100 μ g ml −1 streptomycin, 55 μ M 2-mercaptoethanol, stem cell factor, IL-3, IL-6, FLT3L and thrombopoietin. After 24 h of culture, the cells were transduced with lentiviral shRNA (cloned in FG12-UbiC-GFP), and the GFP-positive infected cells were sorted at 48 h, and 5,000-50,000 cells were plated in complete methylcellulose medium (Methocult H4435, StemCell Technologies). For the colony-formation assays with Gbp, sorted hCD34 + cells from the primary patient specimens were cultured in complete methylcellulose medium with the indicated concentrations of Gbp. Colonies were scored on days 9-14. Bioinformatic analysis of human gene expression. For the focused gene expression analysis of BCAT1, BCAT2 and MSI2 in human CML progression, the GEO dataset GSE4170 was retrieved and analysed using Python version 2.7 and the SciPy statistical toolkit (http://www.scipy.org/). Pearson correlation coefficients were used to find patterns of co-expression. For co-expression analysis of BCAT1 and MSI2 across multiple cancer types, the GEO datasets GSE14671 (CML), GSE10327 (medulloblastoma), GSE20916 (colorectal), GSE14548 (breast) and TCGA datasets LAML (AML) and LUAD (lung adenocarcinoma) were collected and analysed in a similar fashion. analysed with TaqMan Gene Expression Assays: Bcat1 (Mm00500289_m1), Bcat2 (Mm00802192_m1), Gpt1 (Mm00805379_g1), Gpt2 (Mm00558028_m1), Got1 (Mm00494698_m1), Got2 (Mm00494703_m1). Amino acid and keto acid quantification. Leukaemia cells or peripheral blood samples drawn from mice bearing myeloid leukaemia were used for amino acid and keto acid analysis by HPLC-fluorescence detection, as described 32-34 . In brief, 200,000 live leukaemia cells per sample were sorted and washed twice with icecold PBS to remove media components before extraction. The blood plasma was prepared by centrifugation of the peripheral blood samples at 2,000g at 4 °C for 10 min. Plasma fractions were then treated with 45% methanol/45% acetonitrile containing 6-aminocaproic acid (internal standard for amino acid analysis) or α -ketovalerate (internal standard for keto acid analysis) on ice for 10 min. Cell samples were treated with 80% methanol instead of the 45% methanol/acetonitrile mixture. After removing the insoluble particles by centrifugation, the supernatants were collected and dried using a SpeedVac at 30-45 °C. For amino acid quantification, the dried samples were treated with the amine-reactive 4-fluoro-7-nitro-2,1,3-benzoxadizole (NBD-F) to derivatize the amino acids. HPLC separation of NBD-amino acids was performed on an Inertsil ODS-4 column (3.0 mm × 250 mm, 5 μ m, GL Sciences, Tokyo, Japan) at a flow rate of 0.6 ml min −1 . We used two types of mobile phase condition for the separation of 16 amino acids. The mobile phase was water/methanol (55/45, v/v). Fluorescence detection was performed at the emission wavelength of 415 nm with excitation at 360 nm. Measurement of leucine uptake in primary mouse leukaemia cells. Primary mouse leukaemia cells from the spleens of the mice bearing myeloid leukaemia were used for the analysis of leucine uptake essentially as described previously 35, 36 . In brief, live leukaemia cells were sorted and washed with HBSS to remove media components. The cells were incubated at 37 °C for 1-3 min with pre-warmed HBSS containing 10 μ M [(U)-14 C]l-leucine (Moravek, specific activity, 328 mCi mmol −1 ). The cells were subsequently washed twice with cold HBSS and lysed using 100 mM NaOH. The solubilized cell lysates were mixed with the EcoLume liquid scintillation cocktail (MP Biomedicals), and radioactivity was measured using an LS6500 liquid scintillation counter (Beckman Coulter). Leucine uptake was quantified using a calibration curve of [ 14 C]l-leucine reference standard samples. NMR-based metabolic analysis. Cells were cultured and labelled in media supplemented with either 170 μ M [(U)-13 C]l-valine, 30 or 170 μ M [(U)-13 C]KIV sodium salt (for 13 C tracer experiments; Cambridge Isotope Laboratories) or 2 mM [amine- 15 N]l-glutamine (for 15 N tracer experiments; Cambridge Isotope Laboratories). The concentrations are based on the standard RPMI-1640 media formulation. At the time of collection, the cells were washed twice with ice-cold PBS and extracted with 80% methanol on ice for 10 min. After removing the insoluble particles by centrifugation, the supernatants were collected and dried using a SpeedVac at 30 °C. The cell extracts were dissolved in a total volume of 90 μ l 99.96% D 2 O containing 0.1 mM DSS-d6 and transferred to 3-mm NMR tubes (Shigemi). Calibration samples (150-250 mM) were prepared from 98% 15 N-enriched glutamine, glutamic acid, valine, leucine, isoleucine and alanine (Isotec) and 13 C-enriched KIV and 13 C, 15 N-enriched valine (Cambridge Isotope Laboratories) in D 2 O containing 0.1 mM DSS. All signals were identified either with authentic samples or by reference to literature values. Two-dimensional proton correlated spectra (COSY and TOCSY) were also collected in some cases to confirm assignments. The data were collected at 25 °C on Agilent DD2 spectrometers at 600 or 900 MHz equipped with cryogenically cooled probes. The 1 H data were collected with a 20-s relaxation delay for accurate integration. The 15 N data were acquired with a two-dimensional heteronuclear multiple-bond correlation experiment (gNhmbc) derived from the Agilent pulse program library with the transfer delay set for a 15 N-1 H coupling value of 4 Hz. Typically, datasets were 2,000 × 64 complex points with the 15 N dimension set between 30 and 46 p.p.m., and 64 scans per point. The 13 C data were acquired with a two-dimensional heteronuclear single-bond correlation experiment (HSQCAD) from the Agilent pulse program library, and the datasets were 1,202 × 64 complex points with the 13 C dimension set between 10 and 80 p.p.m. with 16 scans per point. One-dimensional spectra were also collected using the same heteronuclear correlation experiments for 15 N and 13 C. The data were processed using MestReNova software (Mestrelab Research). One-dimensional proton data were processed with 0.3 Hz line broadening and polynomial baseline correction. The gNhmbc and HSQC data were processed with linear prediction and zero-filling in the 15 N and 13 C dimensions. Integration was achieved by summing over peak areas with the contribution of noise subtracted in the 15 N spectra. To calculate the concentrations in the 15 N tracer experiments, the 1 H and gNhmbc spectra of the calibration samples were integrated, and a scaling factor was derived from the ratio of the known concentration of each 98% enriched [ 15 N]amino acid and the integral values from the gNhmbc data. These factors are a function of the three-bond coupling between the [ 15 N]amine and β -protons as well as the number of those protons. Therefore, the concentrations of each amino acid in cell extracts could be estimated from their integral values by applying the respective scaling factor. For quantification of 13 C-labelled compounds, the methyl groups in the 1 H and HSQC spectra of the calibration references were integrated, and a scaling factor was derived essentially as described above and used to calculate concentrations from the HSQC data of each sample. Antibodies. Anti-Flag monoclonal antibody M2 (Sigma-Aldrich), anti-MSI2 monoclonal antibody EP1305Y (Abcam) and normal Rabbit IgG PP64B (Millipore) were used for immunoprecipitation. For western blotting, the following antibodies were used: mouse monoclonal BCAT1 (clone ECA39, BD Transduction Laboratories) and Bcat1 OTI3F5 (OriGene), rabbit monoclonal S6K (9202 and 2708), pS6K (9234), AKT (4691), pAKT, T308 (13038) and pAKT, S473 (4060) from Cell Signaling, rabbit monoclonal MSI2 EP1305Y, mouse monoclonal HSP90 F-8 (Santa Cruz Biotech) and mouse monoclonal β -tubulin BT7R (Thermo Fisher Scientific). RNA immunoprecipitation assays. K562 cells were lysed in 50 mM Tris/HCl (pH 7.5) containing 150 mM NaCl, 5 mM EDTA, 1% NP-40, and the Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). We performed immunoprecipitations with anti-Flag, anti-MSI2 or rabbit normal IgG and protein G magnetic beads (Life Technologies) for 1 h at 4 °C. The immunoprecipitated protein-RNA complexes were washed three times with low-and high-salt wash buffers (300 mM and 550 mM NaCl, respectively), followed by three washes in PBS. Total RNAs were purified from the washed beads using an RNAqueous-Micro kit (Ambion) and subjected to RT-qPCR analysis for quantification. The fold enrichment of the transcript amount in the RIP fraction over the amount present in the input sample before RIP (RIP/input) was calculated for each sample. Statistical analysis. Statistical analyses were performed using GraphPad Prism software version 6.0f (GraphPad Software). Data are shown as the mean ± s.e.m. Two-tailed unpaired Student's t-tests or Mann-Whitney U-tests were used to determine statistical significance. For Kaplan-Meier survival analysis, log-rank tests were used for statistical significance (* P < 0.05, * * P < 0.01, * * * P < 0.001). Data availability. Source gel images and Source Data for animal models are included in the Supplementary Information. All NMR spectral data from metabolic analyses have been deposited in Metabolomics Workbench 37 under the project identifier PR000423. All other relevant data are available from the corresponding author upon request. 
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